Abstract
The arrival of the PSA assay in the management of prostate cancer has revolutionized screening practices. However, due to relatively low specificity, PSA promotes the over-diagnosis of indolent cancers and additional examinations and/or treatments responsible for avoidable side effects. Today, the need is for markers likely to target the most serious forms of cancer, which will benefit from new therapies and personalized medicine. The molecular revolution in the field of oncology now affects prostate cancer through RNA markers, fusion genes, or circulating DNA analyzed by the new mixed discipline, biopathology. We propose a review of biomarkers likely to be used in clinical practice for the screening, diagnosis and monitoring of prostate cancer. Emphasis will be placed on the specificity of each marker and the complementarity they are likely to offer in the management of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
